propafenone / Generic mfg. - LARVOL DELTA

Polatuzumab vedotin, zanubrutinib, rituximab, lenalidomide, and prednisone (Pola-ZR2P) as frontline immunochemotherapy in previously untreated DLBCL patients (ASH 2025) - P2 | "She had a history of arrhythmia managed with intermittent propafenone. Pola-ZR2P regimen demonstrated promising efficacy and a manageable safety profile in this cohort of previously untreated DLBCL patients. This report provides clinical evidence on the efficacy and safety of Pola-ZR2P regimen as the frontline immunochemotherapy in previously untreated DLBCL patients. Further enrollment of more patients is necessary to better clarify the effectiveness and safety of Pola-ZR2P regimen as the frontline chemotherapy in DLBCL patients."

Clinical • B Cell Lymphoma • Cardiovascular • Coronary Artery Disease • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroenterology • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pruritus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • TP53

Ivabradine in the treatment of congenital junctional ectopic tachycardia: a case report and review of the literature. (PubMed, Cardiol Young) - "This report presents a case of neonatal-onset congenital junctional ectopic tachycardia treated with cedilanid, amiodarone, and propafenone but persisted in episodes. The review of the literature indicates that ivabradine demonstrates efficacy in the treatment of paediatric junctional ectopic tachycardia, particularly in refractory cases, without significant side effects. These findings suggest that ivabradine has broad applications in the treatment of refractory arrhythmias."

Journal • Cardiovascular • Pediatrics

DRIVE-AF: Dronedarone Rhythm Intervention for Early Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1898 | Not yet recruiting | Sponsor: Inha University Hospital

HEOR • New P4 trial • Atrial Fibrillation • Cardiovascular

Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Non-oncology Drugs. (PubMed, Cancer Res) - "Furthermore, the mTOR and Hippo pathways mediated the response to combined propafenone/hypoglycemia or biguanides/hypoglycemia treatments, respectively, and mTOR or TEAD inhibitors circumvented the need for dietary interventions to enhance cancer cell death. Together, these results indicate that CM-SLP represents a promising approach for integrating metabolic profiling into precision oncology, offering therapeutic avenues tailored to individual patient needs."

Journal • Hypoglycemia • Metabolic Disorders • Oncology

Impact of Dronedarone on Early Recurrence After Catheter Ablation in Patients With Nonparoxysmal Atrial Fibrillation. (PubMed, Cardiovasc Ther) - "In this retrospective study of patients with nonparoxysmal atrial fibrillation after catheter ablation, dronedarone and amiodarone showed a trend toward better efficacy than propafenone in preventing overall early recurrence. Dronedarone demonstrated a specific advantage in preventing early recurrence of atrial flutter."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Long-Term Outcomes and Post-Ablation Medication De-Escalation After Catheter Ablation for Premature Ventricular Complexes: A Nationwide Cohort Study. (PubMed, Int J Gen Med) - "Medication analysis confirmed dose de-escalation, particularly for mexiletine, propafenone, and amiodarone. Radiofrequency catheter ablation was associated with meaningful reductions in antiarrhythmic medication use, underscoring its potential therapeutic and economic benefits. These findings support radiofrequency catheter ablation as a component of long-term management strategies, while future prospective studies are needed to refine candidate selection and timing of intervention."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Usability of CHA2DS2VASC score in predicting the effectiveness and safety of pharmacological cardioversion - data from the multicenter cardioversion with intravenous ANTazoline study. (PubMed, Front Cardiovasc Med) - "Antazoline was used in 59% of patients, amiodarone in 53%, and propafenone in 19%. In this retrospective sub-analysis of the CANT II registry, success of pharmacological cardioversion of AF is not associated with number of comorbidities as assessed by the CHA2DS2VASc score. PCV remains a feasible and generally safe option in emergency and cardiology department practice."

Journal • Atrial Fibrillation • Cardiovascular • Hypotension

Persistent Focal Atrial Tachycardia In A Young Pregnant Woman: When Stability Isn't Safe (AHA 2025) - "Management included two doses of adenosine with transient effect, and escalating doses of metoprolol and propafenone with partial response...In >75% of reviewed cases, FAT was persistent or recurrent, often requiring multiple agents before ablation.Zero-fluoroscopy ablation is safe and effective. A prospective study of 47 pregnant patients showed 100% acute success, no 24-month recurrence, and favorable obstetric outcomes.Multidisciplinary care improves outcomes in pregnant patients with arrhythmias, where coordination among electrophysiology, cardiology, and obstetrics is essential for timely and individualized decision-making."

Clinical • Cardiomyopathy • Cardiovascular • Fatigue • Obstetrics • Pulmonary Disease

Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study. (PubMed, BMC Med) - "Concomitant use of interacting antiarrhythmic drugs does not seem to affect the effectiveness of DOACs but may increase their risk of major bleeding."

Journal • Atrial Fibrillation • Cardiovascular • Ischemic stroke

FLECAINIDE TOXICITY LEADING TO WIDE COMPLEX TACHYARRHYTHMIAS IN THE SETTING OF WORSENING CARDIOMYOPATHY (CHEST 2025) - "CASE PRESENTATION: A 71-year-old male with AF (on flecainide and carvedilol), nonischemic cardiomyopathy, and heart failure with reduced ejection fraction (EF) (with an EF of 35%) presented to the ED with near-syncope after experiencing multiple lightheaded episodes...On Day 2, he had a similar episode of WCT and IV amiodarone was commenced, leading to resolution of WCT...In patients with structural heart disease—particularly those with significantly reduced EF—Class IC agents (flecainide and propafenone) are generally contraindicated due to increased risk of mortality and proarrhythmias [1,6]... This case underscores the risk of flecainide toxicity in patients with advanced structural heart disease and reduced ejection fraction. Close monitoring of the structural status of the heart is essential in patients on class 1C antiarrhythmics."

Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Ventricular Tachycardia

Transcription factors of the Nuclear Factor I (NFI) family control hepatocyte differentiation and cytochrome P450 activity in human liver. (PubMed, Pharmacol Res) - "Recent reports have indicated that the minor allele of the nuclear transcription factor I/B (NFIB), rs28379954 T>C, affects the metabolism of risperidone and clozapine, which are mediated by CYP2D6 and CYP1A2, respectively. First, we reanalyzed the association between rs28379954 T>C and CYP2D6 activity in three independent cohorts exposed to CYP2D6 substrates (propafenone, tamoxifen, and sparteine) which revealed no association...We identified significant downregulation of several metabolic pathways related to hepatic functionality, PPAR signaling, and drug metabolism for NFIB, NFIC, and NFIX, whereas pathways associated with cancer biology were significantly induced. In summary our findings provide further insight into hepatic CYP regulation via the NFI network with implications for the understanding of interindividual variability of drug metabolism."

Journal • Oncology • CYP1A1 • CYP1A2 • CYP2C19 • NFIB • NFIC

Stability study of common vasoactive drugs diluted in five types of solutions. (PubMed, Front Pharmacol) - "Except for amiodarone hydrochloride, nicardipine hydrochloride, propafenone hydrochloride, and diltiazem hydrochloride, which showed significant pH changes after dilution, the pH changes of the other solutions were less than 0.1. Except for isoproterenol hydrochloride, the content of the other tested drugs showed no significant differences within 8 h. When diluted with the five commonly used solutions and stored at room temperature without light protection for 8 h, the tested drugs maintained stable properties."

Journal

Reviewing the use of antiarrhythmic drugs in elderly patients with atrial fibrillation. (PubMed, Expert Rev Cardiovasc Ther) - "Although AADs represent a cornerstone for symptoms relief in patients with AF, these drugs did not show a clinical net benefit compared to a rate control, with a potential increased risk of complications and hospitalizations. Considered also the different pharmacokinetics and the concomitant comorbidities and treatments that characterize older patients, the administration of these drugs should be reserved to selected patients with high burden of AF-related symptoms."

Journal • Review • Atrial Fibrillation • Cardiovascular

In Silico Assessment and Quantitative Estimation of Potential Toxic Impurities From Propafenone (PFN) Through Generic Route and Using UPLC-MS/MS Technique. (PubMed, Biomed Chromatogr) - "This validated approach presented very low LOD and LOQ limits (0.08-0.2 ppm), excellent linearity (coefficients > 0.9944), and a satisfactory recovery range (88.1%-102.8%). The method was sufficient in terms of sensitivity, linearity, precision, accuracy, selectivity, and robustness, and marketed samples analysis also proved that the method could directly apply for the PFN drug substance of real-time sample testing."

Journal

An aggressive electrophysiologist-guided rhythm control strategy significantly reduces hospital admissions in patients presenting with atrial fibrillation in the emergency department. Data from the HE (ESC-WCC 2025) - "Otherwise, intravenous flecainide was administered and upon failure or in case of contraindications to intravenous flecainide (prior home loading with >300mg propafenone or >200mg flecainide), electrical cardioversion was performed...Rate control was performed in 20% with beta-blockers and verapamil... An aggressive electrophysiologist-guided rhythm control strategy for patients presenting with AF in the ED resulted in a significant reduction in hospital admissions."

Clinical • Atrial Fibrillation • Cardiovascular

Early rhythm control in patients with acute decompensated heart failure (ESC-WCC 2025) - "Rhythm control therapy was defined as cardioversion, use of antiarrhythmic drugs (amiodarone, dronedarone, flecainide, or propafenone) or AF ablation. These hypothesis-generating results support the evaluation of early rhythm control for outcome reduction in patients with AHF and AF."

Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

Improving management of patients with atrial fibrillation in the emergency department based on an aggressive rhythm control strategy. The HEROMEDICUS study. (ESC-WCC 2025) - "Otherwise, intravenous flecainide was administered and upon failure or in case of contraindications to intravenous flecainide (prior home loading with >300mg propafenone or >200mg flecainide), electrical cardioversion was performed with the patient fasting for 6 hours and with sedation and analgesia administration (midazolam IV & analgesia IV)...Rate control was performed in 20% with beta-blockers and verapamil... Aggressive rhythm control strategy through implementation of the HEROMEDICUS protocol in the ED showed that 75% of the study population reverted to sinus rhythm and admissions were limited to 4.1%, without compromising safety."

Clinical • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

First-line catheter ablation for atrial fibrillation - lower than recommended doses of antiarrhythmic drugs may have contributed to their inferiority: Analysis of randomized controlled studies comparing ablation with antiarrhythmic drugs. (PubMed, Trends Cardiovasc Med) - "Among the 442 patients randomized to the drug arm, 15% to 43% received flecainide, propafenone, and sotalol at lower than recommended doses...Notably, up to 10% of the patients in the ablation arm were adjunctively treated with antiarrhythmic drugs. This may have contributed to the reported superiority of catheter ablation compared to antiarrhythmic drug therapy."

Journal • Review • Atrial Fibrillation • Cardiovascular

Protective effects of propafenone, propranolol, and amiodarone against isoproterenol-induced lethal arrhythmias in IGF1R deficiency mice. (PubMed, Biochem Biophys Res Commun) - "The study further explored the effects of antiarrhythmic drugs, finding that propranolol and amiodarone effectively mitigated these arrhythmias, reducing mortality rates to 0 %, while propafenone had a less pronounced effect, with a mortality rate of 33.3 %. These findings underscore the potential therapeutic value of targeting IGF1R signaling pathways in the management of stress-induced arrhythmias and highlight the need for further research into the precise molecular mechanisms underlying IGF1R's protective effects and the development of novel antiarrhythmic therapies."

Journal • Preclinical • Cardiovascular

Comparing the Impact of Different Antiarrhythmic Classes on Clinical Outcomes Following Atrial Fibrillation Catheter Ablation. (PubMed, Pharmaceuticals (Basel)) - "Class IC AADs were administered to 62 cases, while the remaining 36 patients received amiodarone following catheter ablation... Class IC and Class III antiarrhythmics show comparable efficacy in terms of preventing ATa recurrence following AF catheter ablation. AAD-related adverse event rates are negligible for short-term use."

Clinical data • Journal • Atrial Fibrillation • Cardiovascular

Immunomodulatory Activity of Propafenone Hydrochloride on Mammalian Macrophages in the Presence of LPS. (PubMed, Cell Biochem Biophys) - "At the clinical setting this information should be taken into the consideration if anti-inflammatory drug utilization is also necessary to prevent extra usage of the drug molecules. In case of infections, the patients who are using propafenone should get immune boosting supplements to be able to cope with the infectious agent."

Journal • Atrial Fibrillation • Cardiovascular • Epilepsy • Infectious Disease • Oncology • CSF2 • IL6 • TNFA

Current practices and knowledge of adenosine administration for paroxysmal supraventricular tachycardia: a multi-province survey in Chinese emergency departments. (PubMed, BMC Emerg Med) - "Emergency physicians, especially those in charge, have a limited understanding of SVT and the appropriate use of adenosine, necessitating further training for this demographic."

Journal • Cardiovascular • Ventricular Tachycardia

Cadmium-immobilizing bacteria utilize octanoic acid and two synthetic compounds to enhance nitrogen fixation in soybeans under cadmium stress. (PubMed, J Exp Bot) - "Our findings reveal a cooperative mechanism wherein both non-nitrogen-fixing bacteria and specific compounds support soybeans' nitrogen-fixation function under Cd stress by regulating bioavailable Cd and rhizobia abundance. Surprisingly, we also found that the synthetic compounds propafenone and levonorgestrel can confer Cd-stress protection to plants."

Journal

Repurposing of propafenone, an FDA approved anti-arrhythmic drug for antileishmanial therapy. (PubMed, Biochimie) - "Cell cycle arrest was detected at the G2/M stage. The data suggests that propafenone has antileishmanial potential and can be evaluated further in an experimental VL model."

FDA event • Journal • Infectious Disease • Metabolic Disorders

Wide complex tachycardia and brugada electrocardiographic pattern induced by propafenone: A rare and unpredictable pro-arrhythmic effect. (PubMed, J Electrocardiol) - "We present a rare patient case, where therapeutic range dosage of propafenone resulted in a wide complex tachycardia, followed by the Brugada ECG pattern during atrial fibrillation. We discuss the possible mechanisms related to this unusual ECG manifestation."

Journal • Atrial Fibrillation • Cardiovascular • Ventricular Tachycardia